GONAL-F RFF Rx
Generic Name and Formulations:
Follitropin alfa (recombinant follicle-stimulating hormone) 75 IU; per vial; pwd for SC inj after reconstitution.
EMD Serono, Inc.
Indications for GONAL-F RFF:
Development of multiple follicles in ovulatory patients undergoing Assisted Reproductive Technology (ART). Induction of ovulation and pregnancy in patients with functional anovulatory infertility without primary ovarian failure. Also, Gonal-F: Induction of spermatogenesis in men with hypogonadotropic hypogonadism without primary testicular failure.
Be fully familiar with infertility treatment and its complications before using this product. See Warnings/Precautions. Individualize. ART: initially 150 IU daily in early follicular phase; usual max 10 days. ART in women with suppressed endogenous gonadotropin levels: <35yrs: initially 150 IU daily; ≥35yrs: initially 225 IU daily. All: adjust dose after 5 days based on response, then by up to 75–150 IU every 3–5 days; max 450 IU/day. Give hCG 5000–10000 Units after follicular development. Induction of ovulation: initially 75 IU daily for 14 days in the first cycle; then determine subsequent doses based on response; if indicated, may increase after the initial 14 days, then every 7 days in increments of up to 37.5 IU; usual max 300 IU/day for up to 35 days. Give hCG 5000 Units one day after last dose. Men: 150 IU three times per week given with hCG 1000 Units three times per week; max 300 IU three times per week. Attain normal serum testosterone levels first by pretreating with hCG 1000–2250 Units 2–3 times per week.
Primary gonadal failure. Uncontrolled thyroid, adrenal, or pituitary disorders. Sex hormone-dependent tumors. Tumors of pituitary gland or hypothalamus. Undiagnosed abnormal uterine bleeding. Ovarian cysts or enlargement. Pregnancy (Cat.X).
Do complete gynecological and appropriate endocrinological exam first. Monitor appropriate lab values. Serious pulmonary conditions. Thromboembolic disorders. If ovaries are enlarged on last day of therapy, or other evidence of ovarian hyperstimulation syndrome (OHSS) occurs, do not give hCG. Discontinue if evidence of OHSS occurs (eg, excessive number of ovarian follicles seen by serum estradiol levels or ultrasound, abdominal pain). Increased risk of ovarian torsion, multi-fetal gestation and births, ectopic pregnancy, spontaneous abortion. Nursing mothers: not recommended.
Women: headache, abdominal pain, OHSS (with or without pulmonary and vascular complications; may be serious), ovarian enlargement or cysts, intermenstrual bleeding, local reactions; rare: ovarian neoplasms, congenital malformations. Men: Distension, acne, breast pain, fatigue, gynecomastia, varicocele, inj site reactions.
Multidose vials—1 (w. syringes); Single-dose vials—1, 10 (w. syringes); Pen—1 (w. needles); Redi-ject—1 (w. needles)
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|